Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
33 Results for "
hepatitis B surface antigen
" in MedChemExpress (MCE) Product Catalog:
Products (33)
33 Results for "hepatitis B surface antigen" in MCE Product Catalog:
4
Cat. No.: HY-P990015
CAS No.: 2645440-65-7
Synonyms: VIR-3434
Cat. No.: HY-147266
Purity: 95.83%
Synonyms: VIR-2218 sodium
Target:
Research Areas:
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .
Cat. No.: HY-P991674
CAS No.: 3033337-14-0
Synonyms: BJT-778
Target:
Research Areas:
Synonyms: RO7445482 sodium
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the
hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .
hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .
Category:
Flavonoids Thymelaeaceae Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology Biflavones Stellera chamaejasme L.
Target:
Cat. No.: HY-P99541
CAS No.: 138660-97-6
Synonyms: anti-hepatitis B; OST 577; SDZ-OST 577
Cat. No.: HY-147266A
CAS No.: 2648009-64-5
Synonyms: VIR-2218
Target:
Research Areas:
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .
HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .
Cat. No.: HY-171181
CAS No.: 2306303-35-3
ZINC20451377 is a small molecule targeting hepatitis B (HBV) surface antigen (HBsAg) and can effectively inhibit wild-type hepatitis B and tenofovir (HY-13910)-resistant hepatitis B .
Cat. No.: HY-N15419
CAS No.: 18145-26-1
Target:
Cat. No.: HY-177300
CAS No.: 1402802-45-2
Research Areas:
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
Cat. No.: HY-P2783
CAS No.: 79386-00-8
Category:
Target:
Cat. No.: HY-173278
Target:
Research Areas:
AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC50 of 3.8 nM. AIC263282 shows an IC50 of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes .
Cat. No.: HY-162327
Target:
Research Areas:
PROTAC PAPD5 degrader 1 is a selective PAPD5 PROTAC degrader. PROTAC PAPD5 degrader 1 induces ubiquitination and degradation of PAPD5 without causing degradation of PAPD7. PROTAC PAPD5 degrader 1 reduces Hepatitis B virus mRNA and Hepatitis B surface antigen levels in vitro. PROTAC PAPD5 degrader 1 inhibits both Hepatitis A virus and Hepatitis B virus. PROTAC PAPD5 degrader 1 can be used for research on Hepatitis A virus infection and Hepatitis B virus infection .
Cat. No.: HY-N3093
CAS No.: 1025023-05-5
Synonyms: (+)-Periglaucine B
Target:
Cat. No.: HY-159987
CAS No.: 2848560-66-5
AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
